Immix Biopharma (IMMX)
(Delayed Data from NSDQ)
$2.05 USD
+0.01 (0.49%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $2.03 -0.02 (-0.98%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IMMX 2.05 +0.01(0.49%)
Will IMMX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for IMMX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IMMX
What Makes Immix Biopharma, Inc. (IMMX) a Good Fit for 'Trend Investing'
Immix (IMMX) CAR-T Therapy IND Cleared by FDA, Stock Down
IMMX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Immix Biopharma, Inc. (IMMX) Is a Great 'Buy the Bottom' Stock Now
Immix (IMMX) Up on Orphan Drug Tag for AL Amyloidosis Therapy
Other News for IMMX
Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
Immix Biopharma Shareholders Back Growth and Governance Changes
RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships
IMMX Stock Earnings: Immix Biopharma Beats EPS for Q1 2024